(Bloomberg) -- Piotr Skowron started his company six
weeks ago and already has one eye on the stock market.
``We have contracts in Poland and abroad, and we want to
sell shares,'' says Skowron, 45, whose biotechnology company
specializes in cloning genes. ``We want to get more capital and
be recognizable across the world.''
Read more at Bloomberg Exclusive News
weeks ago and already has one eye on the stock market.
``We have contracts in Poland and abroad, and we want to
sell shares,'' says Skowron, 45, whose biotechnology company
specializes in cloning genes. ``We want to get more capital and
be recognizable across the world.''
Read more at Bloomberg Exclusive News
No comments:
Post a Comment